Update shared on 04 Nov 2025
Fair value Decreased 1.26%Narrative Update: Analyst Price Target for Olympus Adjusted
Analysts have slightly reduced their fair value estimate for Olympus, lowering the price target from $1,976.43 to $1,951.54. The change is attributed to updated expectations for discount rates and revenue growth.
What's in the News
- Olympus completed a share buyback by repurchasing 20,766,200 shares (1.84%) for ¥37,034.97 million, fulfilling a program announced in May 2025. (Key Developments)
- A global medical device removal action was initiated for ViziShot 2 FLEX (19G) EBUS-TBNA needles manufactured before May 12, 2025, following reports of device components detaching during procedures, with one associated patient death. (Key Developments)
- The U.S. launch of the VISERA S OTV-S500 imaging platform was announced, offering advanced capabilities for ENT and urology applications and supporting improved diagnostic performance. (Key Developments)
- Olympus revised its earnings guidance for the fiscal year ending March 31, 2026, lowering revenue, operating profit, and net profit forecasts from previous estimates. (Key Developments)
Valuation Changes
- Consensus Analyst Price Target has decreased modestly, moving from ¥1,976.43 to ¥1,951.54.
- Discount rate has risen slightly, increasing from 5.70% to 5.86%.
- Revenue growth expectations have declined, lowering from 3.93% to 3.78%.
- Net profit margin has improved marginally, rising from 11.33% to 11.36%.
- Future P/E ratio has edged down, shifting from 20.51x to 20.39x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.